03:02 , Jun 30, 2018 |  BioCentury  |  Finance

Smitten by SMID-caps

Risk is pervasive heading into the third quarter and choppy waters are expected, but 13 buysiders told BioCentury they’re not afraid to stay the course. A politically charged environment is likely to intensify as the midterm...
00:06 , May 5, 2018 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 11 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 3Q; (B) 12-month EPS; Source: Yahoo! Finance, Financial Times, company websites CompanyDatePre/post mkt1Q18 EPS est1Q17 EPSExpected chgMyriad Genetics...
18:47 , Mar 16, 2018 |  BC Week In Review  |  Financial News

Cyteir raises $29M series B

Cyteir Therapeutics Inc. (Cambridge, Mass.) raised $29 million in a series B round led by Venrock on March 8. Existing investor Celgene Corp. (NASDAQ:CELG) participated alongside new investors Lightstone Ventures and DROIA Oncology Ventures. Cyteir plans...
19:51 , Mar 8, 2018 |  BC Extra  |  Financial News

Cyteir raises $29M series B

Cyteir Therapeutics Inc. (Cambridge, Mass.) raised $29 million in a series B round led by Venrock. Existing investor Celgene Corp. (NASDAQ:CELG) participated alongside new investors Lightstone Ventures and DROIA Oncology Ventures. Cyteir plans to begin clinical...
23:09 , Feb 2, 2018 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 12 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 3Q; (B) Nine-month EPS; (C) Fiscal 2Q; (D) During trading hours in Europe; premarket on U.S. exchange;...
06:22 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

FDA approves AZ's Lynparza for breast cancer

FDA approved an sNDA from AstraZeneca plc (LSE:AZN; NYSE:AZN) and partner Merck & Co. Inc. (NYSE:MRK) for ovarian cancer drug Lynparza olaparib to treat patients with germline BRCA-mutated, HER2-negative metastatic breast cancer who have previously...
20:19 , Jan 12, 2018 |  BC Extra  |  Company News

FDA approves AZ's PARP inhibitor for breast cancer

FDA approved an sNDA from AstraZeneca plc (LSE:AZN; NYSE:AZN) and partner Merck & Co. Inc. (NYSE:MRK) for ovarian cancer drug Lynparza olaparib to treat patients with germline BRCA-mutated, HER2-negative metastatic breast cancer who have previously...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
21:14 , Dec 14, 2017 |  BC Innovations  |  Emerging Company Profile

Backpacks for CARs

Torque Therapeutics Inc. is making “backpacks” for immune cell therapies that release immune stimulatory molecules at particular doses and locations to boost the cells’ activity without risking systemic exposure. The technology could augment the success...
23:25 , Nov 15, 2017 |  BC Extra  |  Company News

Management tracks: Outpost, Torque

Genitourinary play Outpost Medicine LLC (Indianapolis, Ind.) named Scott Byrd president and CEO. He succeeds interim CEO David Socks, who will remain on the company's board. Byrd was president and COO at the Acacia Pharma...